Myambutol (Ethambutol Hydrochloride)

Ethambutol blocks the arabinosyl transferases EmbA, EmbB and EmbC that are required for building the arabinogalactan layer of the mycobacterial cell wall. This inhibition hampers cell‑wall synthesis, making the bacteria more vulnerable to other anti‑TB drugs and limiting bacterial growth.

The prescribed dose of Myambutol is individualized by the treating physician based on factors such as the patient’s age, weight, renal function, and the overall tuberculosis regimen. No fixed dosing can be provided without a medical prescription.

The pregnancy category for Ethambutol Hydrochloride is listed as unknown. It should only be used during pregnancy or lactation when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the Myambutol product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Ethambutol is distinct from other first‑line agents such as Isoniazid or Rifampicin. While Isoniazid targets mycolic acid synthesis and Rifampicin inhibits RNA polymerase, Ethambutol interferes with cell‑wall arabinogalactan formation. This complementary mechanism makes it valuable in combination therapy, though it has a unique safety profile, especially regarding visual toxicity.

Myambutol should be stored below 25 °C in its original packaging, protected from moisture and direct light. The product must be kept in a dry, temperature‑controlled environment and handled according to standard aseptic techniques for injectable sterile powders.

Myambutol is supplied as a sterile powder for reconstitution and is administered by a healthcare professional via intramuscular or intravenous injection, according to the prescribing physician’s instructions and the specific tuberculosis treatment protocol.

The most serious adverse events include optic neuritis leading to significant visual loss, severe hepatic toxicity, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome or anaphylaxis. Prompt discontinuation and medical evaluation are required if any of these events occur.

Myambutol should be avoided in patients with known hypersensitivity to Ethambutol or any component of the formulation, in individuals with pre‑existing severe optic nerve disease, and in those where the risk–benefit ratio is unfavorable, such as patients with uncontrolled hepatic or renal impairment without dose adjustment.